Otofa (Rifamycin Sodium)

Rifampicin, the active ingredient in Otofa, is a rifamycin antibiotic presented as a powder for oral suspension use. It treats Mycobacterium tuberculosis infections and is used in multi‑drug regimens for pulmonary and extrapulmonary tuberculosis in adults and children.

GNH USA supplies Otofa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Rifampicin is a broad‑spectrum antibacterial that acts on mycobacterial infections, particularly the tuberculosis complex. It is employed in several clinical contexts: - Pulmonary tuberculosis: contributes to bacterial clearance and reduces relapse risk. - Extrapulmonary tuberculosis: aids in controlling disease at sites such of dissemination. - Leprosy (Hansen disease): part of multidrug therapy to limit bacterial proliferation. - Prophylaxis for mening mening of contacts of TB cases : pre‑empt development of active TB infection. - Staphyl  st  infection  : used  as  adjacent  therapy  in  certain  resistant  strains  when  combined  with  other  agents.

Rifampicin may elicit a range of adverse reactions, from mild to severe, depending on individual sensitivity and treatment duration.

Common Side Effects: - Hepatotoxicity: elevated liver enzymes. - Gastrointestinal upset: nausea, vomiting, abdominal discomfort. - Skin reactions: rash, pruritus. - Flu‑like symptoms: fever           g     g    ...    ... ...  ...  ...  …  ... …  …  ... …  … ... …  ...  … …  g  … ... …  - Red       …  …  … … … … … … … … … … … … … … … … … … … … … … … … … … -  …  …  …  …  …  …  …  …  …  … …

Serious or Rare Side Effects: - Severe hepatotoxicity: jaundice, hepatitis. - Hemolytic anemia                 ...   - Thrombocytopenia   …   - Acute                                …   -                               ");